(RTTNews) - Jupiter Neurosciences, Inc. (JUNS), a clinical-stage pharmaceutical company focused on neuroinflammation and CNS disorders, on Monday announced a new manufacturing agreement with Catalent Pharma Solutions.
Under the agreement, Catalent will produce JOTROL softgel capsules for Jupiter's upcoming Phase 2a clinical trial in Parkinson's disease.
JOTROL is a resveratrol-based therapeutic designed to significantly enhance bioavailability while minimizing gastrointestinal side effects.
The Phase 2a trial will evaluate the safety, tolerability, and pharmacokinetics of JOTROL in Parkinson's patients over a three-month period.
Catalent will manufacture both active and placebo batches of JOTROL, adhering to current Good Manufacturing Practices or CGMP standards.
This partnership is a critical milestone for advancing JOTROL's clinical development.
Christer Rosén, CEO of Jupiter Neurosciences, emphasized the importance of Catalent's expertise in accelerating JOTROL's development and bringing the innovative treatment closer to patients with Parkinson's disease.
Currently, JUNS is trading at $0.93 up by 8.79%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
